Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2

Conditions

Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Thyroid Carcinoma, Anaplastic 2Respiratory Tract Neoplasms 2Colorectal Neoplasms 2Thyroid Neoplasms 1Neoplasm Metastasis 1Liposarcoma 1Advanced Non-small Cell Lung Cancer (NSCLC) 1Advanced Cancer 1

Interventions

Paclitaxel 4pembrolizumab 2pazopanib 2efatutazone 2Sorafenib 2Radiotherapy, Intensity-Modulated 2trametinib 1tislelizumab 1surufatinib 1spartalizumab 1sapanisertib 1lenvatinib 1fosbretabulin 1dabrafenib 1crolibulin 1combretastatin 1cabozantinib 1atezolizumab 1abemaciclib 1Taxes 1Imatinib Mesylate 1Gefitinib 1Doxorubicin 1Docetaxel 1Cisplatin 1Carboplatin 1CUDC-907 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Thyroid Carcinoma, Anaplastic × efatutazone × Clear all
NCT02152137 2025-01-27

Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
19 enrolled 13 charts
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT00603941 2020-09-16

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Daiichi Sankyo

Phase 1/2 Terminated
19 enrolled 13 charts
EndocrineHead & Neck

Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡